publication date: Mar. 31, 2016


Tocagen Expands Phase II/III Trial, Begins Enrolling in Canada


Tocagen Inc. expanded its phase II/III clinical trial Toca 5, and is now enrolling patients in Canada. The trial first began enrolling patients in the U.S. in December 2015.

The study compares the combination of Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release 5-fluorocytosine) to standard of care in patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection.

The study’s primary endpoint is overall survival. Investigators may choose chemotherapy (lomustine or temozolomide) or antiangiogenic therapy (bevacizumab) for the control arm.

“With enrollment ongoing in the United States, expanding the study to include patients in Canada is an important milestone for the Canadian brain tumor community as well as for Tocagen,” said Jamey Skillings, chief medical officer of Tocagen. “We are grateful to the various individuals and groups who contributed to this achievement, and we look forward to opening additional sites internationally as we continue to advance this potential new treatment option for patients with high grade glioma.”

The Canadian Brain Tumour Consortium is facilitating the Toca 5 trial in Canada under the consortium’s chair, James Perry, who is head of division of neurology at Sunnybrook Health Sciences Centre at the University of Toronto.

Tocagen’s cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs) which are designed to selectively integrate into the DNA of cancer cells which then serve as factories for these … Continue reading CCL March – Tocagen Expands Phase II/III Trial, Begins Enrolling in Canada

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.